Tratamiento médico de la insuficiencia cardiaca por disfunción diastólica
MF Jiménez-Navarro, JM García-Pinilla… - Revista Española de …, 2006 - Elsevier
La insuficiencia cardiaca por disfunción sistólica hace referencia a un síndrome clínico
caracterizado por signos y/o síntomas de insuficiencia cardiaca en el contexto de una …
caracterizado por signos y/o síntomas de insuficiencia cardiaca en el contexto de una …
ACE inhibitors versus ARBs: comparison of practice guidelines and treatment selection considerations
AE Miller, M Cziraky, SA Spinler - Formulary, 2006 - search.proquest.com
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs)
play a role in the treatment of hypertension (HTN) and heart failure (HF). The literature …
play a role in the treatment of hypertension (HTN) and heart failure (HF). The literature …
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial
EL Eisenstein, S Yusuf, V Bindal, MG Bourassa… - Journal of cardiac …, 2006 - Elsevier
BACKGROUND: The Digitalis Investigation Group (DIG) clinical train randomized 6800
congestive heart failure patients (ejection fraction≥ 45%) to a daily regimen of either digoxin …
congestive heart failure patients (ejection fraction≥ 45%) to a daily regimen of either digoxin …
Candesartan for the management of heart failure: More than an alternative
RS McKelvie - Expert Opinion on Pharmacotherapy, 2006 - Taylor & Francis
Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the
gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have …
gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have …
The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS
P Lechat - European Heart Journal Supplements, 2006 - academic.oup.com
The treatment of chronic heart failure (CHF) has changed greatly during the last two
decades, moving from therapy based on a haemodynamic model to treatments targeting the …
decades, moving from therapy based on a haemodynamic model to treatments targeting the …
[PDF][PDF] The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients
V Jearnsujitwimol, S Eiam-Ong, T Kanjanabuch… - J Med Assoc …, 2006 - researchgate.net
Objective: The objective of this study was to examine the effects of angiotensin II receptor
blocker (ARB), used as an antihypertensive medication, on peritoneal membrane …
blocker (ARB), used as an antihypertensive medication, on peritoneal membrane …
Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique: que …
JM Krzesinski, C Montrieux, A Scheen - Revue Médicale de Liège, 2006 - orbi.uliege.be
Les inhibiteurs du système rénine-angiotensine ont gagné leur lettre de noblesse pour la
prévention secondaire des complications cardio-vasculaires et néphrologiques. Les …
prévention secondaire des complications cardio-vasculaires et néphrologiques. Les …
Carvedilol reduces aldosterone release in systolic heart failure
A Aggarwal, J Wong, DJ Campbell - Heart, Lung and Circulation, 2006 - Elsevier
BACKGROUND: Treatment of advanced systolic heart failure (HF) with the aldosterone
antagonist spironolactone on the background of angiotensin converting enzyme inhibition …
antagonist spironolactone on the background of angiotensin converting enzyme inhibition …
Hypertension and heart failure: diagnosis and management
KA Courville, HO Ventura - Current hypertension reports, 2006 - Springer
Heart failure continues to be a significant problem faced by today's health care professional.
Heart failure remains one of the principal causes of cardiovascular morbidity and mortality …
Heart failure remains one of the principal causes of cardiovascular morbidity and mortality …